StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

CRISPR Therapeutics's EV/EBITDA was 10.7× on Jul 29, 2022, against 156.4× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2022Jul 29, 202210.7×+3.0
2021Dec 31, 20217.8×−148.6
2020Jul 31, 2020156.4×–

More CRISPR Therapeutics figures

See a number that looks wrong?